Aurinia Pharmaceuticals (AUPH) insider buying
4 open-market purchases of AUPH by Aurinia Pharmaceuticals's executives and directors since August 2025, worth $21M in total, from SEC Form 4 filings.
The most recent: Kevin Tang bought $7M on February 27, 2026.
The biggest buyer over the period is Kevin Tang: 4 purchases, $21M.
By year
| Year | Purchases | Value |
|---|---|---|
| 2026 | 1 | $7M |
| 2025 | 3 | $14M |
Biggest buyers
| Insider | Buys | Value |
|---|---|---|
| Kevin Tang | 4 | $21M |
Every purchase
Newest first. From SEC Form 4 filings. Insider buying across the market.
Questions
Are Aurinia Pharmaceuticals insiders buying the stock?
4 open-market purchases of AUPH by Aurinia Pharmaceuticals's executives and directors since August 2025, worth $21M in total, from SEC Form 4 filings. The most recent: Kevin Tang bought $7M on February 27, 2026.
What counts as insider buying here?
Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.
From Aurinia Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.